Core Viewpoint - Traditional Chinese medicine (TCM) is becoming an important force in promoting global health, with Tianyao Daren Tang Group actively participating in international cooperation and product innovation to spread TCM benefits beyond borders [1][2]. Group 1: Company Initiatives - Tianyao Daren Tang's flagship product, "Suxiao Jiuxin Wan," was registered as a prescription drug in Russia in 1997, marking it as the first Chinese patent medicine to receive such approval, which set a benchmark for TCM products entering international markets [1]. - Since 2017, Tianyao Daren Tang has established a stable partnership with Russian TCM companies, leading to the registration of various products, including the Dami Wan series and Jing Wan Hong as dietary supplements and cosmetics in Russia [2]. - The company emphasizes not only product export but also the promotion of TCM culture through international exhibitions and academic exchanges, enhancing local understanding and trust in TCM [2]. Group 2: Future Directions - Tianyao Daren Tang aims to deepen cooperation with countries in the Shanghai Cooperation Organization (SCO) in the field of TCM, focusing on clinical research, technology exchange, and mutual recognition of standards to contribute to a global health community [2][3].

21世纪经济报道记者 闫硕 北京报道 近日，由BMJ集团主办，北京中医药大学协办，扬子江药业公益支持的《BMJ循证医学》圆桌会在北京 成功举办。本次圆桌会聚焦"构建传统医学高质量证据框架、创新中西医协同整合机制、中医临床干预 的策略实践"三大主题，旨在推动传统医学循证研究标准化发展，探索中西医协同整合创新医疗 （002173）模式，更通过跨学科、跨国界深度碰撞，为中医药文化创新与传承搭建国际交流平台，为全 球医学研究范式革新注入强劲动能。 针对上述挑战，与会专家提出多项创新性解决方案。刘清泉教授表示："我们可以探索'循证-临床-信 息'三位一体的转化平台建设，利用人工智能技术对海量文献进行自动提取与结构化处理，生成面向不 同层级医生的'分层指南'——为专家提供详尽证据链，为基层医生提供简洁操作手册。" 同时，刘清泉教授指出，辨证论治是中医认知疾病的核心，推动传统经验转化为临床实效，需先通过辨 证明确疾病本质与核心治法，再灵活适配药物。他以呼吸道传染病治疗为例：团队以传承千年的中医经 验方为基础，历经7年系统临床研究，纳入1370例患者开展实验，成功将其研发为治疗甲流的中成药； 2020年新冠疫情期间，又基于" ...

Group 1 - The core viewpoint of the article highlights that Yiling Pharmaceutical (002603) has been awarded the "Outstanding Contribution Award for Beautiful China" in the 2025 ESG Model Enterprise List for its exceptional practices in ecological environment protection and sustainable development [1][2] - The evaluation gathered over 40 enterprises from various sectors including high-end manufacturing, green energy, digital technology, finance, and consumption, aiming to depict a corporate image that internalizes ESG concepts as a core driving force for high-quality development in the context of Chinese modernization [1][2] - Yiling Pharmaceutical has integrated environmental protection into its corporate development strategy, establishing an ESG practice system characterized by the traditional Chinese medicine industry, which includes ecological planting of medicinal materials and innovative green production processes [1][2] Group 2 - The recognition of Yiling Pharmaceutical signifies the high acknowledgment of ESG practices within the traditional Chinese medicine sector, providing a model for sustainable development in the industry [2] - The ongoing ESG model enterprise evaluation initiated by Observer Network since 2024 aims to promote the transition of ESG from a concept to actionable practices, focusing not only on environmental performance but also on social responsibility and corporate governance [2] - Under the guidance of high-quality development principles, Chinese enterprises like Yiling Pharmaceutical demonstrate that economic benefits and environmental benefits can mutually promote each other, contributing Chinese wisdom and solutions to global sustainable development [2]

中新网上海9月1日电 (记者 陈静)多位专家1日在沪一致认为，矿物药作为中医药宝库的重要组成部分， 深入推进其现代化研究不仅是丰富和发展中医药理论体系的关键着力点，也是实现矿物药临床精准应用 与转化、服务"健康中国"战略的必然路径。 "第二届矿物药学术研讨会"1日在沪举行，旨在通过构建高水平的学术交流平台推动矿物药的科技创新 与产学研用融合，加速科研成果的转化。本次会议邀请了多位该领域权威专家学者，着重围绕矿物药基 础研究和应用领域面临的关键科学和技术问题展开深入研讨。 在采访中，记者了解到，磐龙玉自2015年在吉林省磐石市龙岗山脉被发现以来，因其富含锶、硒等多种 人体有益微量元素，逐渐显现出其在矿物药领域的研究潜力。 成立于2019年的上海中医药大学磐龙玉矿物药国际研究院，是中国首个矿物药专业研究机构，致力于开 展各种矿物药资源的药用价值研究和应用转化。该研究院与上海中医药大学科研人员通力合作，研发了 磐龙玉紫草凝胶剂和用于治疗关节疼痛的磐龙玉理疗设备。他们还发现磐龙玉外用具有消炎、助眠等功 效。在本次研讨会上，研究院方面发布了磐龙玉的化学物质组成、新制剂研究、抗炎药理功效和安全性 研究的阶段性成果。相关研 ...

Core Viewpoint - The integration of traditional Chinese medicine (TCM) and Western medicine is being prioritized at the national level in China, with systematic measures being implemented to modernize and internationalize TCM [1][3]. Group 1: Policy and Strategic Development - The "14th Five-Year Plan for TCM Development" emphasizes the promotion of evidence-based research in TCM [1]. - Continuous support for the collaborative practice of TCM and Western medicine is evident through various policies [1]. - The national strategy aims to enhance the clinical efficacy of TCM in managing chronic diseases and infectious diseases [1]. Group 2: Clinical Practice and Research - Current collaboration between TCM and Western medicine often remains superficial, lacking deep integration of theoretical frameworks [1]. - There is a need for standardized efficacy evaluation criteria to facilitate the promotion of collaborative treatment protocols [1]. - Research indicates that TCM has shown positive results in treating conditions like acute cough and sore throat, providing strong evidence for its efficacy as an alternative to antibiotics [5][6]. Group 3: International Recognition and Challenges - The inclusion of TCM in clinical guidelines of developed countries is crucial for its international recognition [4]. - Key challenges for TCM's acceptance in the UK include the lack of GMP certification, the need for balancing standardization with personalization in treatment, and overcoming biases against TCM [5][6]. - Training and evidence-based communication are essential for the effective implementation of clinical guidelines that include TCM [6]. Group 4: Methodological Innovations - The development of a robust evidence system to support TCM's clinical value is critical, focusing on optimizing research methodologies [7][8]. - There is a call for high-quality practice guidelines and the exploration of personalized treatment methods that align with TCM principles [9][10]. - The integration of modern technologies like genomics and systems biology can enhance the understanding of TCM's biological foundations [9][10]. Group 5: Global Integration and Future Directions - The exploration of TCM and Western medicine integration offers valuable insights for global traditional and modern medicine fusion [10][11]. - The Chinese experience in TCM and Western medicine integration serves as a reference for global healthcare systems [11][12]. - Future efforts should focus on scientific support and patient-centered approaches to deepen the integration of TCM and Western medicine [12][15].

Core Viewpoint - Traditional Chinese medicine (TCM) is gaining popularity and recognition at the 2025 Shanghai Cooperation Organization (SCO) Summit, showcasing its potential as a bridge for health and cultural exchange among SCO member countries [3][5]. Group 1: TCM Promotion and Impact - The TCM therapy point at the SCO Summit is providing services such as pulse diagnosis and massage, attracting international media attention and positive feedback from participants [3]. - Since 2014, Tianjin University of Traditional Chinese Medicine has collaborated with a Russian medical institution to promote TCM therapies, drawing patients from SCO countries like Russia, Kazakhstan, and Uzbekistan to Tianjin for treatment [5]. - TCM is not only being practiced but also taught, with Tianjin University establishing long-term partnerships with universities in SCO countries to offer TCM-related courses and training programs [5]. Group 2: Educational Exchange and Cultural Dissemination - International students from SCO countries, such as Mongolia and Pakistan, are studying TCM in Tianjin, with many becoming cultural ambassadors for TCM upon returning to their home countries [7]. - Currently, there are 140 international students from SCO countries at Tianjin University, making up 28% of the total international student population, indicating a growing interest in TCM education [7]. - The increasing collaboration and exchange in TCM are expected to enhance health benefits for the populations of SCO member states [7].

Core Insights - The company is undergoing a brand rejuvenation aimed at attracting younger consumers by integrating traditional Chinese medicine with modern lifestyle trends [1][3][6] - The Chinese traditional medicine market is projected to reach 510.2 billion yuan by 2024, with the 18-35 age group accounting for 83.7% of health consumption [3][6] - The company is shifting from being a product supplier to a health lifestyle advocate, emphasizing the importance of connecting with younger consumers through familiar scenarios and methods [6][15] Brand Promotion Strategies - The company has launched various interactive events and campaigns, such as the "Urban Workplace Health Season" and participation in the FIBA OPEN event, to engage with young consumers [8][11] - Innovative marketing approaches include live streaming events that combine traditional elements with modern engagement tactics, such as the ancient-style live broadcast in Beijing [6][11] - The company has effectively utilized e-commerce platforms and social media to reach younger demographics, conducting promotional activities around key dates and leveraging popular platforms like Xiaohongshu [15] Product Focus and Market Engagement - The company has tailored its product offerings to meet the health needs of young professionals, particularly addressing issues like stress relief and fatigue [11][13] - Successful campaigns have led to significant sales growth, such as a 301% increase in sales for a specific product during a promotional event [11] - The company is actively involved in community outreach and educational initiatives, such as "Traditional Chinese Medicine Culture in Schools," benefiting over 60,000 individuals [15]

Group 1 - The article highlights the transformation of the Longfu Temple area in Beijing into a new cultural consumption landmark, with the integration of traditional Chinese medicine and modern health concepts by Tongrentang's Zhi Ma Health store [1] - The Longfu Temple area, with over 500 years of history, is being revitalized through unique brands that enhance its role as a space for fashion, trends, and lifestyle aesthetics [1] - The initiative aims to inject new momentum into urban renewal, making the Longfu Temple district a significant cultural consumption destination [1]

人民网约翰内斯堡8月31日电 （记者邹松）四川名医海外工作室（南非）与约翰内斯堡大学联合主办的首届"锦医丝路奖"颁奖仪式8月30日在南非约翰 内斯堡大学隆重举行。来自南非豪登省卫生厅的临床经理高赫洛·莫莱费、非洲中医及针灸学会、顺势治疗医学会、约翰内斯堡大学补充医学系师生以及南 非各地中医药从业者、学术代表和社会各界人士共百余人齐聚一堂，共同见证这一推动中医药国际化发展的新举措。 "锦医丝路奖"设立旨在激发中医药学生和从业者的学习热情，推动中医药文化在非洲的广泛传播与深入发展。在四川省中医药学会的指导下，该奖项由 非洲中医及针灸学会主办，四川名医海外工作室（南非）承办，奖项总奖金达25万兰特，分设锦医丝路传播奖、锦医丝路杏林奖、锦医丝路岐黄奖和锦医丝 路岐黄学者四个类别，分别表彰在中医药文化传播、临床服务与技术推广、教育科研、文化建设等领域作出突出贡献的个人与机构。这是非洲中医药领域首 个兼具广泛影响力与综合性评价体系的重要奖项。 嘉宾与获奖者合影。非洲中医及针灸学会供图 四川名医海外工作室（南非）负责人胡紫景教授致辞。非洲中医及针灸学会供图 四川名医海外工作室（南非）成立于2025年，由成都市中西医结合医院 ...

Core Insights - The company reported a significant increase in net profit, reaching 150 million yuan, a year-on-year growth of 41.6% [1] - EBITDA reached 270 million yuan, reflecting a year-on-year increase of 37.3%, indicating strong operational efficiency and cost control [1] - The impressive performance is attributed to the dual strategies of cost reduction and business focus, enhancing profitability and operational resilience [1] Financial Performance - Revenue for the first half of 2025 was 1.49 billion yuan, representing a growth of 9.5% [2] - Growth drivers included the "same city expansion + new city development" strategy, with new branches entering profitability and contributing stable revenue [2] - The number of repeat patients increased by 14.8% due to refined operational tools and AI health assistants, further boosting overall performance [2] Profitability and Efficiency - The company's gross profit margin improved to 30.6%, benefiting from a decrease in expense and cost ratios due to scale growth [2] - High-margin self-priced product revenue surged by 209.1%, alongside significant growth in self-funded projects like traditional Chinese medicine therapies [2] - Administrative and sales expense ratios decreased, contributing to the 37.3% growth in EBITDA, showcasing enhanced profitability [2] Future Outlook - The company is positioned to continue delivering high profit growth and quality optimization, supported by national policies promoting the traditional Chinese medicine industry [2]